Socioeconomic Phenotype Index (SPI™): Reframing Social Determinants as Biological Terrain
- Sep 29, 2025
- 6 min read
Updated: May 7
Executive Summary
The Socioeconomic Phenotype Index (SPI™) represents a paradigm shift in how health science conceptualizes the role of socioeconomic status. For decades, poverty, access barriers, and discrimination have been categorized as “social determinants of health” (SDOH). While this framing acknowledges their impact, it relegates them to the periphery of medical science. SPI™ reframes these determinants as phenotypes, measurable biological terrains that directly influence disease onset, chronicity, flare cycles, and treatment responsiveness. By integrating socioeconomic status into phenotype classification, SPI™ provides researchers, clinicians, and policymakers with a quantifiable tool for stratifying risk, designing trials, and ensuring equity in care delivery.
Background
The field of precision medicine has traditionally focused on biological phenotypes such as genetic mutations, hormonal imbalances, or immune dysregulation. Social determinants, by contrast, are treated as “context” , important, but external to the biological model. However, robust evidence demonstrates that chronic socioeconomic instability produces biological signatures:
Immune modulation: Chronic stress alters cytokine production and inflammatory pathways.
Endocrine disruption: Financial or housing insecurity triggers sustained cortisol elevation and HPA axis dysregulation.
Neurological impact: Prolonged exposure to discrimination and trauma rewires neural circuits linked to autonomic regulation.
These are not “external” modifiers but phenotypic drivers. The absence of a structured model has left a gap in both research and clinical practice, one that SPI™ fills.
The SPI™ Model
Traditional models treat poverty, access gaps, and discrimination as “external factors.” SPI™ reframes them as biological terrain modifiers that affect immune response, flare cycles, and remission probability. The system scores patients across three domains, Structural Security, Access to Care, and Psychosocial Buffering, then generates a composite index that stratifies risk and resilience.
Domains
SPI™ is composed of three domains, each scored on a 0–3 scale:
Structural Security
Housing stability
Financial security
Food security
Educational access
Access to Care
Insurance coverage
Geographic proximity
Provider availability
Cultural and linguistic competence
Psychosocial Buffering
Community and family networks
Institutional trust
Exposure to violence or discrimination
Presence of protective social capital
Formula
SPI Score = (Structural Security + Access to Care + Psychosocial Buffering) ÷ 3
Each domain is scored from 0–3, with higher values representing higher socioeconomic burden.
Range:
0.0–0.9 = Advantage phenotype
1.0–1.9 = Moderate risk phenotype
2.0–2.9 = High risk phenotype
3.0 = Extreme risk phenotype
Real-World Example with Calculation
A patient with:
Structural Security = 2 (chronic housing + financial instability)
Access to Care = 1 (insurance gaps, but some access)
Psychosocial Buffering = 3 (domestic violence, systemic exclusion)
SPI Score = (2 + 1 + 3) ÷ 3 = 2.0 → High risk phenotype
Implication: This patient is predisposed to more frequent flares, lower treatment responsiveness, and higher hospitalization risk. Interventions must integrate both clinical and socioeconomic stabilization strategies.
Applications
Clinical Trials
SPI™ enables stratification of participants not just by biology but by socioeconomic terrain. This prevents trial failure due to unrecognized socioeconomic phenotypes that alter drug efficacy.
Health Systems & Insurers
SPI™ offers a measurable framework for risk adjustment and reimbursement. High-SPI patients can be flagged for enhanced care coordination, reducing long-term costs.
Policy & Access
By redefining socioeconomic status as phenotype, SPI™ transforms equity into a biological and economic imperative, not an optional consideration. It provides a hard-data foundation for CMS, NIH, and FDA to enforce broadly accessible standards.
Why It Works
Biological Validity: Chronic socioeconomic stress reshapes immune, endocrine, and neurological function.
Quantifiable Action: Converts SDOH into a measurable, reproducible score.
Licensing Value: Provides a modular scoring overlay that can be integrated into CYNAERA’s terrain intelligence ecosystem (Pathos™, VitalGuard™, SymCas™, etc.).
Scalability: SPI™ can be implemented globally, with regional calibration for cultural and economic variation.
Conclusion
The Socioeconomic Phenotype Index (SPI™) advances equity science into the domain of measurable biology. By treating socioeconomics as a phenotype rather than a peripheral determinant, SPI™ offers a framework that is scientifically valid, operationally practical, and commercially scalable. Incorporated into CYNAERA’s modular systems, SPI™ has the potential to reshape clinical trials, health policy, and patient outcomes, ensuring that the invisible terrain of inequity is finally quantified and addressed.
CYNAERA Framework Papers and Core Research Libraries
This paper draws on a defined subset of CYNAERA Institute white papers that establish the methodological and analytical foundations of CYNAERA’s frameworks. These publications provide deeper context on prevalence reconstruction, remission, combination therapies and biomarker approaches. Our Long COVID Library, ME/CFS Library, Lyme Library, Autoimmune Library and CRISPR Remission Library are also in depth resources.
Author’s Note:
All insights, frameworks, and recommendations in this written material reflect the author's independent analysis and synthesis. References to researchers, clinicians, and advocacy organizations acknowledge their contributions to the field but do not imply endorsement of the specific frameworks, conclusions, or policy models proposed herein. This information is not medical guidance.
Patent-Pending Systems
Bioadaptive Systems Therapeutics™ (BST) and affiliated CYNAERA frameworks are protected under U.S. Provisional Patent Application No. 63/909,951. CYNAERA is built as modular intelligence infrastructure designed for licensing, integration, and strategic deployment across health, research, public sector, and enterprise environments.
Licensing and Integration
CYNAERA supports licensing of individual modules, bundled systems, and broader architecture layers. Current applications include research modernization, trial stabilization, diagnostic innovation, environmental forecasting, and population level modeling for complex chronic conditions. Basic licensing is available through CYNAERA Market, with additional pathways for pilot programs, institutional partnerships, and enterprise integration. For media, podcast, research, or licensing inquiries related to the Mankeeping Index™, contact CYNAERA.
About the Author
Cynthia Adinig is the founder of CYNAERA, a modular intelligence infrastructure company that transforms fragmented real world data into predictive insight across healthcare, climate, and public sector risk environments. Her work sits at the intersection of AI infrastructure, federal policy, and complex health system modeling, with a focus on helping institutions detect hidden costs, anticipate service demand, and strengthen planning in high uncertainty environments.
Cynthia has contributed to federal health and data modernization efforts spanning HHS, NIH, CDC, FDA, AHRQ, and NASEM, and has worked with congressional offices including Senator Tim Kaine, Senator Ed Markey, Representative Don Beyer, and Representative Jack Bergman on legislative initiatives related to chronic illness surveillance, healthcare access, and data infrastructure. In 2025, she was appointed to advise the U.S. Department of Health and Human Services and has testified before Congress on healthcare data gaps and system level risk.
She is a PCORI Merit Reviewer, currently advises Selin Lab at UMass Chan, and has co-authored research with Harlan Krumholz, MD, Akiko Iwasaki, PhD, and David Putrino, PhD, including through Yale’s LISTEN Study. She also advised Amy Proal, PhD’s research group at Mount Sinai through its CoRE advisory board and has worked with Dr. Peter Rowe of Johns Hopkins on national education and outreach focused on post-viral and autonomic illness. Her CRISPR Remission™ abstract was presented at CRISPRMED26 and she has authored a Milken Institute essay on artificial intelligence and healthcare.
Cynthia has been covered by outlets including TIME, Bloomberg, Fortune, and USA Today for her policy, advocacy, and public health work. Her perspective on complex chronic conditions is also informed by lived experience, which sharpened her commitment to reforming how chronic illness is understood, studied, and treated. She also advocates for domestic violence prevention and patient safety, bringing a trauma informed lens to her research, systems design, and policy work. Based in Northern Virginia, she brings more than a decade of experience in strategy, narrative design, and systems thinking to the development of cross sector intelligence infrastructure designed to reduce uncertainty, improve resilience, and support institutional decision making at scale.
References
Academic
Marmot, M., & Wilkinson, R. G. (Eds.). (2005). Social determinants of health (2nd ed.). Oxford University Press.
Braveman, P., & Gottlieb, L. (2014). The social determinants of health: It’s time to consider the causes of the causes. Public Health Reports, 129(1_suppl2), 19–31.
McEwen, B. S., & Gianaros, P. J. (2010). Central role of the brain in stress and adaptation: Links to socioeconomic status, health, and disease. Annals of the New York Academy of Sciences, 1186(1), 190–222.
Williams, D. R., Lawrence, J. A., & Davis, B. A. (2019). Racism and health: Evidence and needed research. Annual Review of Public Health, 40, 105–125.
Adler, N. E., & Rehkopf, D. H. (2008). U.S. disparities in health: Descriptions, causes, and mechanisms. Annual Review of Public Health, 29, 235–252.
CYNAERA
CYNAERA Institute. (2025). Pathos Symptom-Based Scoring Table. CYNAERA White Paper Series.
CYNAERA Institute. (2025). VitalGuard™: Predictive Flare Intelligence from Environmental Terrain. CYNAERA White Paper Series.
CYNAERA Institute. (2025). BRAGS™: Bias Research Accountability Grading System. CYNAERA Equity Modules.
CYNAERA Institute. (2025). SymCas™: Predictive Symptom Sequencing for Chronic Illness Flares. CYNAERA Systems Library.
CYNAERA Institute. (2025). PULSE™: Underreporting Detection in Public Health Data. CYNAERA White Paper Series.
Comments